Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Duloxetine and pregabalin: safe and effective for the long-term treatment of fibromyalgia?

Abstract

This Practice Point commentary discusses the first two trials of long-term drug treatment in fibromyalgia. In Russell et al.'s study, 33% of patients receiving 6-month treatment with 60 mg/day duloxetine responded to therapy; the number needed to treat was seven. In the three treatment arms, 15% (60 mg/day duloxetine), 27% (120 mg/day duloxetine) and 13% (placebo) of patients discontinued treatment because of adverse events (the most common being nausea [24%] and fatigue [14%]). In Crofford et al.'s study, 32% of patients who received pregabalin had loss of therapeutic response, compared with 61% of patients treated with placebo. The discontinuation rate due to adverse events (dizziness in 36% of cases and somnolence in 22%) during the randomized treatment phase was 16% with pregabalin and 7% with placebo. This commentary discusses the implications of these trials for clinical practice and considers areas for future research in the field. In view of the current results, duloxetine and pregabalin could be administered together and as part of multimodal and multidisciplinary therapy, but treatment should 'start low and go slow'.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wolfe F et al. (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33: 160–172

    Article  CAS  Google Scholar 

  2. Vitton O et al. (2004) A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 19 (Suppl 1): S27–S35

    Article  CAS  Google Scholar 

  3. Arnold LM et al. (2004) A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depression disorder. Arthritis Rheum 50: 2974–2984

    Article  CAS  Google Scholar 

  4. Crofford LJ et al. (2005) Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52: 1264–1273

    Article  CAS  Google Scholar 

  5. Russell IJ et al. (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136: 432–444

    Article  CAS  Google Scholar 

  6. Crofford LJ et al. (2008) Fibromyalgia relapse evaluation and efficacy for durability on meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136: 419–431

    Article  CAS  Google Scholar 

  7. Yunus MB (2007) Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 37: 339–352

    Article  Google Scholar 

  8. Carville SF et al. (2007) EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 67: 536–541

    Article  Google Scholar 

Download references

Acknowledgements

The author would like to thank Rosemary Ancelle-Park at Public Health, Paris, France.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author has received grant/research support from Bristol-Myers Squibb, Jazz Pharmaceuticals and Pierre Fabre, and is a consultant for Bristol-Myers Squibb, Grünenthal, Eli Lilly, Pfizer and Pierre Fabre.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Serra, E. Duloxetine and pregabalin: safe and effective for the long-term treatment of fibromyalgia?. Nat Rev Neurol 4, 594–595 (2008). https://doi.org/10.1038/ncpneuro0936

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0936

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing